“The present problem has uncovered some structural weaknesses from the EU’s medicines source chain and a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She advisable that offer chain issues be dealt with in an EU pharmaceutical technique expected to